10-KPeriod: FY2006

ALNYLAM PHARMACEUTICALS, INC. Annual Report, Year Ended Dec 31, 2006

Filed March 12, 2007For Securities:ALNY

Summary

This 2006 10-K filing for Alnylam Pharmaceuticals, Inc. (ALNY) details a company in the early stages of drug development, with a significant focus on RNA interference (RNAi) therapeutics. Alnylam had no products approved for sale and generated no product revenue during the period. Its primary activities revolved around research and development, with substantial investments in its scientific platform and pipeline. The company's financial strategy was heavily reliant on equity financing and strategic partnerships to fund its extensive R&D efforts. Investors should note that Alnylam was operating at a loss, a typical characteristic of pre-revenue biotechnology firms. The company's valuation and future prospects were therefore tied to the successful advancement of its drug candidates through clinical trials and regulatory approval. The risk factors section is crucial for understanding the inherent uncertainties and challenges associated with developing novel therapeutics in this nascent field, including the long timelines, high costs, and significant regulatory hurdles involved. The company's ability to secure future funding and maintain its intellectual property were critical for its long-term survival and growth.

Key Highlights

  • 1Alnylam Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapeutics based on RNA interference (RNAi).
  • 2The company had no approved products for sale and reported no product revenue for the fiscal year ended December 31, 2006.
  • 3Significant investment in research and development activities, reflecting the company's focus on building its scientific platform and pipeline.
  • 4Reliance on equity financing and strategic collaborations for funding, with substantial net losses reported due to high R&D expenditures.
  • 5The filing highlights the early-stage nature of the company and the inherent risks associated with developing novel drug technologies, including regulatory and clinical trial uncertainties.
  • 6Key personnel and scientific expertise are critical assets, with a strong emphasis on intellectual property protection.

Frequently Asked Questions

Alnylam Pharmaceuticals is focused on the development of RNA interference (RNAi) therapeutics. As of the filing date (March 12, 2007, for the fiscal year ending December 31, 2006), the company had no approved products and was in the research and development phase, with no product revenues generated.

The company's operations are primarily funded through equity financings and strategic collaborations. Given its pre-revenue status, Alnylam reported significant net losses due to substantial investments in research and development activities.

The primary risks include the inherent uncertainties of developing novel RNAi therapeutics, the long and costly drug development process, potential clinical trial failures, regulatory hurdles, the need for substantial future funding, and competition in the biopharmaceutical industry. Protecting its intellectual property is also a key concern.

No, as of the fiscal year ended December 31, 2006, Alnylam Pharmaceuticals had not generated any revenue from product sales, as it had no approved products on the market.